Pure Global AI
NCT06333678Recruiting

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

A Randomized Phase II Study of Sotorasib Versus Continued Consolidation Durvalumab in Patients With KRAS G12C Mutant Locally Advanced Non-small Cell Lung Cancer (LANSCLC) With Persistent ctDNA Defined Minimal Residual Disease
Memorial Sloan Kettering Cancer CenterPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-Small Cell Lung Cancer
Drug/Device/Intervention
Durvalumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Memorial Sloan Kettering Cancer Center
Location
Basking Ridge,Middletown,Montvale,Commack,Harrison,New York,Uniondale, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Mar 20, 2024
End date
Mar 01, 2027
Enrollment
160 participants
Primary outcome

Progression-free survival (PFS)

Summary

In this study, the researchers will look at whether having participants switch from
 durvalumab to sotorasib when they have detectable minimal residual disease (MRD) is an
 effective treatment approach for locally advanced non-small cell lung cancer (LA-NSCLC). The
 researchers will see whether this switch to sotorasib can control LANSCLC longer compared to
 the treatment approach of staying on durvalumab (and not switching to sotorasib).

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06333678
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06333678 through Pure Global AI's free database. This Phase 2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 160 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.